Amicus CEO Exits With $14.6M As BioMarin Merger Closes

The BioMarin merger converts equity into a fixed cash sum per share, removing future upside risk for the seller. Each option previously granted was cancelled and exchanged for a cash payment tied to the $14.50 merger price minus the exercise price.

Campbell disposed of 1,008,680 units, including 689,467 common shares and 319,213 vested restricted stock units, generating $14.63 million at the $14.50 share price. The 103,578 stock options listed in the filing were converted into cash rights based on the spread between the merger price and their specific exercise prices.

With FOLD trading under ticker FOLD and BioMarin under BMRN, the transaction finalizes a 100% exit from the prior equity structure. What to watch next is how this near-complete divestment aligns with the company’s operational milestones under new ownership.